Clinical Research

Found 141,175 articles

• Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met Primary Endpoint of Progression-Free Survival (PFS) as First-Line Therapy for Advanced or Recurrent Endometrial Carcinoma

  2/3/2023

  Merck today announced that the Phase 3 NRG-GY018 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival (PFS) for the treatment of patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status.

• BD Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

  2/3/2023

  BD (Becton, Dickinson and Company) today announced a new instrument for single-cell multiomics analysis that will enable scientists to run high-throughput studies without sacrificing sample integrity – potentially accelerating time to discovery across a wide range of disciplines including immunology, genetic disease research, and cancer and chronic disease research.

• Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials

  2/3/2023

  Personalis, Inc. and Moderna, Inc. today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940.

• Neurent Medical Announces Limited Market Release of NEUROMARK® System to Treat Chronic Rhinitis

  2/3/2023

  Neurent Medical today announced its NEUROMARK ® Rhinitis Neurolysis Therapy (RNT) is now commercially available in limited U.S. markets.

• PaxMedica, Inc. Secures $3.2 Million Growth Capital From Lind Partners

  2/3/2023

  PaxMedica, Inc. today announced that the Company has signed a funding agreement for net proceeds of $3.2 million with Lind Global Partners II, LP.

• GENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

  2/3/2023

  Genetic Technologies Limited is pleased to announce the Company will launch a ‘World First’ Comprehensive Risk Assessment Test which evaluates a women’s risk of developing Breast and/or Ovarian Cancer either from a hereditary genetic mutation or from the far more common familial or sporadic cancer.

• Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma

  2/3/2023

  Gracell Biotechnologies Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared Gracell's Investigational New Drug (IND) application and the Company can proceed to initiate a Phase 1b/2 clinical trial in the U.S. of GC012F, an autologous CAR-T therapeutic candidate, for the treatment of relapsed/refractory multiple myeloma (RRMM).

• PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation

  2/3/2023

   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has been named the winner of 2023 EURORDIS Black Pearl Company Award for Innovation.

• Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch

  2/3/2023

  Revive Therapeutics Ltd. is pleased to announce it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. to evaluate the delivery of 3,4-Methylenedioxy​methamphetamine using PharmaTher’s novel microneedle patch delivery technology.

• Mnemo Therapeutics and Institut Curie Announce Two Key Publications in Science Immunology Highlighting Novel Approach to Identify Unknown, Therapeutically Relevant Cancer-Specific Targets

  2/3/2023

  Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, has announced publication of two groundbreaking scientific studies developed at Institut Curie, its closest academic collaborator, in the journal Science Immunology.

• 

  Does CRISPR Have a Bias Problem?

  2/2/2023

  Recent scientific papers report errors in CRISPR gene editing linked to ancestry.

• CoImmune Announces Novel Engineered CAR T Cells Improve Anti-Tumor Activity and Reverse Immunosuppression in Preclinical Models

  2/2/2023

  CoImmune, Inc. today announced that preclinical models show CAR T cells engineered with OrexiCAR technology to secrete a CD47-SIRPα checkpoint blocker have improved anti-tumor activity and reverse myeloid immunosuppression in tumors.

• Babson Diagnostics Unveils Brand Identity for Next-Generation Blood Testing

  2/2/2023

  Babson Diagnostics, a science-first, health care technology company, today announced BetterWay™ Blood Testing, the name of its new diagnostic blood testing service that is designed around the most important element of testing – the customer.

• Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 Tissue

  2/2/2023

  Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360 ® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.

• INOVIO Reports Positive Phase 1b Results for INO-4201 as an Ebola Booster for rVSV-ZEBOV (Ervebo®)

  2/2/2023

  INOVIO today announced positive results from a Phase 1b clinical trial evaluating INO-4201, a DNA vaccine candidate, as a booster in healthy adult participants who previously received a single injection of Ervebo.

• Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

  2/2/2023

  Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 ('4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb in August 2021, has entered Phase 1 clinical trials in the United States.

• Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010

  2/2/2023

  Oligomerix, Inc. today announced the dosing of its first subjects in the company’s Phase 1a clinical trial evaluating lead candidate OLX-07010.

• Volta Medical Announces Completion of Patient Enrollment in TAILORED-AF Clinical Trial for Treatment of Atrial Fibrillation

  2/2/2023

  Volta Medical today announced the completion of patient enrollment in the randomized controlled clinical trial, TAILORED-AF, evaluating VX1-guided ablation compared to a ‘standard of care’ anatomical ablation approach.

• Singular Genomics Joins the 10x Genomics Compatible Partner Program

  2/2/2023

  Singular Genomics Systems, Inc. today announced its G4 Sequencing Platform demonstrated compatibility with the 10x Genomics’ Chromium Single Cell platform through the 10x Compatible Partner Program (CPP).

• Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

  2/2/2023

  Anavex Life Sciences Corp. today announced the total enrollment of 92 patients with Rett syndrome for the ANAVEX®2-73 ( blarcamesine ) EXCELLENCE Phase 2/3 study in Rett syndrome patients ages ≥ 5 years to 17 (inclusive).